CA2387819A1 - Compositions a liberation prolongee pour le traitement de pathologies induites par le systeme nerveux central - Google Patents

Compositions a liberation prolongee pour le traitement de pathologies induites par le systeme nerveux central Download PDF

Info

Publication number
CA2387819A1
CA2387819A1 CA002387819A CA2387819A CA2387819A1 CA 2387819 A1 CA2387819 A1 CA 2387819A1 CA 002387819 A CA002387819 A CA 002387819A CA 2387819 A CA2387819 A CA 2387819A CA 2387819 A1 CA2387819 A1 CA 2387819A1
Authority
CA
Canada
Prior art keywords
active compound
sustained
release
composition
isovaleramide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002387819A
Other languages
English (en)
Inventor
David S. Wells
Thomas B. Marriott
Lian G. Rajewski
James D. Pipkin
John L. Haslam
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shire NPS Pharmaceuticals Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2387819A1 publication Critical patent/CA2387819A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Reproductive Health (AREA)
  • Anesthesiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Cette invention concerne des compositions à libération prolongée permettant d'administrer des concentrations thérapeutiques d'isovaleramide, d'acide isovalérique et de certains composés structurellement apparentés pour le traitement de certaines pathologies, notamment de l'épilepsie et de la spasticité, dont l'état peut être amélioré grâce à une modulation de l'activité du système nerveux central. La capacité qu'ont ces compositions de maintenir la dose thérapeutique du médicament dans le sérum à des niveaux relativement constants pendant des périodes prolongées rend possible leur administration à raison d'une ou deux fois par jour.
CA002387819A 1999-10-19 2000-10-19 Compositions a liberation prolongee pour le traitement de pathologies induites par le systeme nerveux central Abandoned CA2387819A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16021099P 1999-10-19 1999-10-19
US60/160,210 1999-10-19
PCT/US2000/041267 WO2001028516A2 (fr) 1999-10-19 2000-10-19 Compositions a liberation prolongee pour le traitement de pathologies induites par le systeme nerveux central

Publications (1)

Publication Number Publication Date
CA2387819A1 true CA2387819A1 (fr) 2001-04-26

Family

ID=22575965

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002387819A Abandoned CA2387819A1 (fr) 1999-10-19 2000-10-19 Compositions a liberation prolongee pour le traitement de pathologies induites par le systeme nerveux central

Country Status (8)

Country Link
EP (1) EP1225888A2 (fr)
JP (1) JP2003512311A (fr)
CN (1) CN1409630A (fr)
AU (1) AU780505B2 (fr)
CA (1) CA2387819A1 (fr)
MX (1) MXPA02003976A (fr)
TW (1) TWI252761B (fr)
WO (1) WO2001028516A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6589994B1 (en) 1996-08-30 2003-07-08 Nps Pharmaceuticals, Inc. Treating a variety of pathological conditions, including spasticity and convulsions, by effecting a modulation of CNS activity with isovaleramide, isovaleric acid, or a related compound
MY142204A (en) 2002-07-25 2010-10-29 Pharmacia Corp Pramipexole once-daily dosage form
WO2006012603A2 (fr) * 2004-07-22 2006-02-02 Nps Pharmaceuticals, Inc. Analogues de l'isovaleramide, composition pharmaceutique contenant ces analogues et methode permettant de traiter des maladies ou des affections du systeme nerveux central
CA2576386A1 (fr) 2004-08-13 2006-02-16 Boehringer Ingelheim International Gmbh Preparation d'une pastille a autorisation de sortie elargie, contenant du pramipexole ou un sel de pramipexole pharmaceutiquement acceptable, procede de fabrication et d'utilisation de cette pastille
PL1789021T3 (pl) * 2004-08-13 2012-04-30 Boehringer Ingelheim Int Preparat tabletkowy o przedłużonym uwalnianiu zawierający pramipeksol lub jego farmaceutycznie dopuszczalną sól
US20070134315A1 (en) * 2005-12-08 2007-06-14 Viera Michael L Orally administrable extended release pellet and tablet formulations of a highly water soluble compound

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL128724A (en) * 1996-08-30 2003-05-29 Nps Pharma Inc Pharmaceutical compositions containing isovaleric acid derivatives for treating various neurological pathologies

Also Published As

Publication number Publication date
JP2003512311A (ja) 2003-04-02
TWI252761B (en) 2006-04-11
MXPA02003976A (es) 2003-09-25
AU1969501A (en) 2001-04-30
WO2001028516A3 (fr) 2002-02-21
CN1409630A (zh) 2003-04-09
AU780505B2 (en) 2005-03-24
WO2001028516A2 (fr) 2001-04-26
EP1225888A2 (fr) 2002-07-31

Similar Documents

Publication Publication Date Title
KR100280099B1 (ko) 방출 개시 제어 및 방출 속도 제어형 제제
ES2606463T3 (es) Combinación de formas de dosificación de levodopa/carbidopa de liberación inmediata y liberación controlada
EP2217217B1 (fr) Compositions pharmaceutiques de prégabaline à libération contrôlée
EP1940361B1 (fr) Formes de dosage pharmaceutique possedant des proprietes de liberation controlee et/ou immediate
US6576260B2 (en) Sustained-release form of administration containing tramadol saccharinate
KR20160045728A (ko) 디메틸푸마레이트를 포함하는 일일 저용량 투여용 약제학적 조성물
US20110135723A1 (en) Pharmaceutical compositions containing pregabalin
JP2015536956A (ja) ヒドロモルホンおよびナロキソンを含む医薬組成物
JP2004521910A (ja) トラマドール系薬剤
US11717501B2 (en) Magnesium threonate compositions and uses thereof
US20150164920A1 (en) Controlled release formulation comprising mesalamine
US7235258B1 (en) Sustained-release formulations for treating CNS-mediated disorders
AU780505B2 (en) Sustained-release formulations for treating CNS-mediated disorders
US20050220873A1 (en) Pharmaceutical dosage forms having immediate and controlled release properties that contain a GABAB receptor agonist
BR112014013374B1 (pt) Comprimidos de acamprosato e usos de acamprosato referência cruzada aos pedidos relacionados
WO2004024128A2 (fr) Composition pharmaceutique a liberation modifiee
US20210290557A1 (en) Multi-particulate pharmaceutical composition, immediate release pellets, sustained release pellets, enteric release pellets and use thereof
CN107362161B (zh) 一种复方卡托普利硝苯地平脉冲缓释制剂及其制备方法
AU2005202728A1 (en) Sustained-release formulations for treating CNS-mediated disorders
US20050220874A1 (en) Pharmaceutical dosage forms having immediate release and controlled release properties that contain a GABAB receptor agonist
RU2292877C2 (ru) Лекарственная ретард-форма, содержащая сахаринат трамадола
US8962020B2 (en) Long-acting and controlled release formulations of 2-[(3-chlorophenyl) amino] phenylacetic acid
US20050220864A1 (en) Pharmaceutical dosage forms having controlled release properties that contain a GABAB receptor agonist
KR20150123302A (ko) 특정한 체외 용해 프로파일 또는 약리역학 파라미터를 갖는 도네페질의 약제학적 조성물

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead